Disclosure: We earn commissions on purchases made through our links. This never influences our scores. Editorial policy
Citicoline
Citicoline is worth a try if your goal is attention, focus, or supporting memory as you age, but the case is narrower than the marketing suggests.
- Evidence
- Mixed Evidence
- Category
- Cognitive & Nootropics
- Best form
- Cognizin (Kyowa Hakko branded citicoline, used in most US healthy-adult and older-adult RCTs, FDA NDI on file)
- Effective dose
- 250-500mg daily for healthy attention and memory
- Lab tested
- 3 of 8 products
- Category
- Cognitive & Nootropics
- Best form
- Cognizin (Kyowa Hakko branded citicoline, used in most US healthy-adult and older-adult RCTs, FDA NDI on file)
- Effective dose
- 250-500mg daily for healthy attention and memory
- Lab tested
- 3 of 8 products
Key takeaways
- →Modest but real attention and memory benefits at 250-500mg/day in healthy adults; nothing dramatic, but better-evidenced than most nootropics.
- →Cognizin is the form used in most US clinical trials; generic citicoline is the same molecule at a lower price but not standardized to Cognizin's specs.
- →Acute stroke and TBI thesis did not hold up: the largest trials (ICTUS, COBRIT) were negative despite earlier positive smaller studies.
- →Generally well-tolerated; skip or use cautiously with bipolar disorder due to anecdotal mania reports and with bradycardia at very high doses.
What Is Citicoline?
Citicoline is worth a try if your goal is attention, focus, or supporting memory as you age, but the case is narrower than the marketing suggests. The strongest data are from small to mid-size Cognizin trials in healthy adolescents, healthy adult women, and healthy older adults with age-associated memory impairment, where 250-500mg per day for 4-12 weeks produced modest but real improvements in attention, psychomotor speed, and episodic memory. The mechanism is plausible: oral CDP-choline raises plasma choline and uridine in a dose-related way, supplying substrate for phosphatidylcholine synthesis, the dominant phospholipid in neuronal membranes.
The acute stroke story is less flattering. Early European trials and meta-analyses suggested benefit, but the large industry-funded ICTUS trial in 2,298 patients found no advantage over placebo on the global stroke scale at 90 days. A 2020 Cochrane review of 10 RCTs concluded the evidence is low-quality and shows little to no difference for mortality or disability. The COBRIT trial in 1,213 traumatic brain injury patients was also flatly negative at 2000mg/day for 90 days. So the IV/high-dose acute neuroprotection thesis has not held up under bigger, better-controlled trials.
The middle ground is mild cognitive impairment and post-stroke cognitive recovery. The IDEALE trial in 349 elderly patients with mild vascular cognitive impairment found significant MMSE improvement at 9 months on 1000mg/day, and several smaller open-label trials suggest citicoline may help cognitive recovery in chronic post-stroke patients. The signal is real but the trials are mostly open-label, Italian, and industry-linked, so treat this as promising rather than settled.
For glaucoma, a small Parisi RCT and several follow-ups suggest citicoline may stabilize visual evoked potentials and pattern ERGs in open-angle glaucoma. Interesting niche but not a reason most people would buy citicoline. ADHD adjunct, depression, and methamphetamine recovery have preliminary signals only.
Practical bottom line: 250-500mg/day of Cognizin (or generic citicoline if you want to save money) is reasonable if you want a modestly better-evidenced focus aid than most nootropics. Do not expect it to do anything dramatic, and do not expect it to rescue acute stroke or TBI.
Does It Work? The Evidence
How A-F grades workAttention, focus, and psychomotor speed in healthy adults
McGlade 2012 RCT (n=60 adult women, 250-500mg x 28d): improved CPT-II attentional focus and inhibition; McGlade 2019 RCT (n=75 adolescent males, 250-500mg x 28d): improved attention and psychomotor speed
Episodic and overall memory in healthy older adults
Nakazaki 2021 RCT (n=100 older adults with age-associated memory impairment, 500mg/day x 12 weeks): significantly greater improvement in episodic and composite memory vs. placebo
Mild vascular cognitive impairment in the elderly
Cotroneo 2013 IDEALE study (n=349, 1000mg/day x 9 months): significant MMSE improvement vs. control; multiple smaller European trials suggest similar direction
Acute ischemic stroke recovery
Davalos 2012 ICTUS trial (n=2,298): no benefit on global stroke scale at 90 days; Marti-Carvajal 2020 Cochrane review of 10 RCTs: little to no difference in mortality or disability, low-quality evidence
Traumatic brain injury
Zafonte 2012 COBRIT trial (n=1,213, 2000mg/day x 90d): no improvement in functional or cognitive status vs. placebo
Open-angle glaucoma (visual function)
Parisi 1999 RCT (n=40, 1000mg/day IM x 60d): significant improvement in VEP and PERG parameters; several small follow-up trials by the same group
ADHD adjunct, depression, methamphetamine recovery
Scattered small trials; no replicated, well-powered RCTs
| Grade | Claimed Benefit | Key Studies | Our Verdict |
|---|---|---|---|
| B | Attention, focus, and psychomotor speed in healthy adults | McGlade 2012 RCT (n=60 adult women, 250-500mg x 28d): improved CPT-II attentional focus and inhibition; McGlade 2019 RCT (n=75 adolescent males, 250-500mg x 28d): improved attention and psychomotor speed | Early Signal |
| B | Episodic and overall memory in healthy older adults | Nakazaki 2021 RCT (n=100 older adults with age-associated memory impairment, 500mg/day x 12 weeks): significantly greater improvement in episodic and composite memory vs. placebo | Early Signal |
| B | Mild vascular cognitive impairment in the elderly | Cotroneo 2013 IDEALE study (n=349, 1000mg/day x 9 months): significant MMSE improvement vs. control; multiple smaller European trials suggest similar direction | Early Signal |
| B | Acute ischemic stroke recovery | Davalos 2012 ICTUS trial (n=2,298): no benefit on global stroke scale at 90 days; Marti-Carvajal 2020 Cochrane review of 10 RCTs: little to no difference in mortality or disability, low-quality evidence | Conflicted |
| B | Traumatic brain injury | Zafonte 2012 COBRIT trial (n=1,213, 2000mg/day x 90d): no improvement in functional or cognitive status vs. placebo | Ineffective |
| C | Open-angle glaucoma (visual function) | Parisi 1999 RCT (n=40, 1000mg/day IM x 60d): significant improvement in VEP and PERG parameters; several small follow-up trials by the same group | Early Signal |
| C | ADHD adjunct, depression, methamphetamine recovery | Scattered small trials; no replicated, well-powered RCTs | Not There Yet |
How to Choose: Forms, Doses & What Matters
Clinical dose: 250-500mg daily for healthy attention and memory; 1000-2000mg daily in stroke and cognitive impairment trials
Best forms: Cognizin (Kyowa Hakko branded citicoline, used in most US healthy-adult and older-adult RCTs, FDA NDI on file), Generic citicoline / CDP-choline (cheaper but not standardized to Cognizin's specs; pharmacology is the same molecule)
Most healthy-adult trials used 250mg or 500mg per day, often as a single morning dose or split into two doses (e.g., 250mg morning and 250mg afternoon). Cognitive impairment and stroke recovery trials used 1000-2000mg/day, typically split twice daily. Food is not required but does not hurt. Effects on attention can be noticed within a few days to a couple of weeks; the older-adult memory trial ran 12 weeks before reading out. Take earlier in the day if you find it activating; some users report sleep disruption when dosed late.
Who Should Take Citicoline?
Healthy adults wanting a modestly evidence-backed focus and attention support, especially for sustained mental work. Older adults with age-associated memory complaints (Nakazaki 2021 used 500mg/day for 12 weeks). People with mild vascular cognitive impairment under physician guidance. Anyone looking to stack a low-stim cognitive aid with caffeine for attention without adding more stimulant load.
Who Should Avoid It?
Not for everyone
Side Effects & Safety
Product Scores
8 products scored on dosing accuracy, third-party testing, cost per effective dose, and label transparency.
The Scorecard: 8 Products Compared
Cognizin Citicoline Capsules 250mg, 60ct
Nootropics Depot$17.99 ÷ 60 days at 250mg/day (1 serving × 250mg)
Nootropics Depot is the rare brand that publishes per-lot citicoline CoAs publicly; 180ct version offers better per-day pricing
Prices checked 2026-04-25. Cost shown is per clinically effective daily dose, not per pill.
Cognizin Citicoline 250mg, 150ct
Healthy Origins
$29.99 ÷ 150 days at 250mg/day (1 serving × 250mg)
Healthy Origins was an early Kyowa Hakko Cognizin licensee and is consistently the cheapest per-day Cognizin option on Amazon
Prices checked 2026-04-25. Cost shown is per clinically effective daily dose, not per pill.
Citicoline (CDP Choline) 250mg
Jarrow Formulas$24.95 ÷ 119 days at 250mg/day (1 serving × 250mg)
Jarrow's Cognizin SKU is one of the longest-running citicoline products on the US market and uses the exact form most healthy-adult trials tested
Prices checked 2026-04-25. Cost shown is per clinically effective daily dose, not per pill.
Citicoline (CDP-Choline) 250mg, 60ct
Life Extension$18.00 ÷ 60 days at 250mg/day (1 serving × 250mg)
Reasonable swap for Jarrow if you already buy from Life Extension and want to keep brand consolidation
Prices checked 2026-04-25. Cost shown is per clinically effective daily dose, not per pill.
Cognizin Citicoline 1000mg, 60ct (2-pack)
Swanson
$59.99 ÷ 120 days at 1000mg/day (1 serving × 1000mg)
The right pick if you want to mirror the IDEALE or Cotroneo cognitive-impairment dose; for plain focus, the 250mg SKUs are cheaper per effective dose
Prices checked 2026-04-25. Cost shown is per clinically effective daily dose, not per pill.
CDP Choline (Citicoline) 300mg, 60ct
Double Wood Supplements$15.95 ÷ 59 days at 300mg/day (1 serving × 300mg)
Pick this if Cognizin's premium does not feel worth it and you trust Double Wood's general third-party testing program
Prices checked 2026-04-25. Cost shown is per clinically effective daily dose, not per pill.
Cognizin Citicoline 500mg, 60ct
Bestvite
$23.99 ÷ 60 days at 500mg/day (1 serving × 500mg)
Bestvite is a smaller US brand that licenses Cognizin; appealing if you want to hit Nakazaki's 500mg dose in one capsule and avoid stearates
Prices checked 2026-04-25. Cost shown is per clinically effective daily dose, not per pill.
CDP Choline (Citicoline) 300mg, 60ct
Nutricost$14.95 ÷ 60 days at 300mg/day (1 serving × 300mg)
Workhorse pick for cost-conscious buyers who do not need the Cognizin label and accept Nutricost's GMP-only quality stance
Prices checked 2026-04-25. Cost shown is per clinically effective daily dose, not per pill.
Full Comparison
| Category | Cognizin Citicoline Capsules 250mg, 60ct Nootropics Depot | Cognizin Citicoline 250mg, 150ct Healthy Origins | Citicoline (CDP Choline) 250mg Jarrow Formulas | Citicoline (CDP-Choline) 250mg, 60ct Life Extension | Cognizin Citicoline 1000mg, 60ct (2-pack) Swanson | CDP Choline (Citicoline) 300mg, 60ct Double Wood Supplements | Cognizin Citicoline 500mg, 60ct Bestvite | CDP Choline (Citicoline) 300mg, 60ct Nutricost |
|---|---|---|---|---|---|---|---|---|
| Brand Score | 92/100Winner | 91/100 | 90/100 | 88/100 | 84/100 | 83/100 | 82/100 | 80/100 |
| Dosing & Form | 25/25Winner | 25/25 | 25/25 | 25/25 | 23/25 | 22/25 | 25/25 | 22/25 |
| Purity | 22/25Winner | 19/25 | 19/25 | 19/25 | 19/25 | 19/25 | 16/25 | 16/25 |
| Value | 22/25 | 24/25Winner | 23/25 | 21/25 | 19/25 | 23/25 | 22/25 | 23/25 |
| Transparency | 23/25Winner | 23/25 | 23/25 | 23/25 | 23/25 | 19/25 | 19/25 | 19/25 |
| Cost/Day | $0.30 | $0.20Winner | $0.21 | $0.30 | $0.50 | $0.27 | $0.40 | $0.25 |
| Dose/Serving | 250mg | 250mg | 250mg | 250mg | 1000mg | 300mg | 500mg | 300mg |
| Form | Cognizin Citicoline (capsule) | Cognizin Citicoline (vegan capsule) | Cognizin Citicoline (capsule) | Cognizin Citicoline (vegetarian capsule) | Cognizin Citicoline (vegetarian capsule) | Generic Citicoline / CDP-Choline (capsule) | Cognizin Citicoline (vegetarian capsule) | Generic Citicoline / CDP-Choline (vegetarian capsule) |
| Third-Party Tested | ✓ Yes | No | No | ✓ Yes | No | ✓ Yes | No | No |
| Proprietary Blend | No | No | No | No | No | No | No | No |
Frequently Asked Questions
What is the difference between Cognizin and generic citicoline?
Chemically they are the same molecule (cytidine-5'-diphosphocholine). Cognizin is the branded form made by Kyowa Hakko under FDA NDI status, with a published certificate of analysis and the pharmaceutical-grade specs used in most US clinical trials (McGlade, Nakazaki, etc.). Generic citicoline from reputable brands (Double Wood, Nutricost) is typically the same molecule at a lower price but without Cognizin's standardization paperwork. If you want the form that has the trials behind it, Cognizin is the safer bet; if you prioritize price and trust the brand's third-party testing, generic is reasonable.
Citicoline vs alpha-GPC vs choline bitartrate - which should I take?
All three raise plasma choline, but they are not interchangeable. Choline bitartrate is the cheapest but the least efficient at raising brain choline and has a fishy aftertaste at high doses. Alpha-GPC is more bioavailable to the brain and has the strongest acute power-output data in athletes. Citicoline (CDP-choline) raises plasma choline and uridine and has the best healthy-adult attention and older-adult memory data. For focus and memory, citicoline. For acute strength and power output, alpha-GPC. For just hitting a daily choline target cheaply, choline bitartrate or eggs.
How fast does citicoline work?
Some users report a subtle attention lift within the first few days. The published trials are longer: McGlade ran 28 days for attention effects in healthy adults, Nakazaki ran 12 weeks for memory in older adults, and IDEALE ran 9 months for vascular cognitive impairment. If you do not feel anything in 2-4 weeks at 500mg/day, it is unlikely to do much for you.
Can I stack citicoline with caffeine?
Yes, and there is one small RCT (Bruce 2014) showing a citicoline-caffeine beverage improved sustained attention and working memory more than placebo. Citicoline does not add stimulant load, so it is a reasonable way to extend a coffee's mental endurance without doubling up on caffeine. Common stack: 100-200mg caffeine plus 250-500mg citicoline in the morning.
Did citicoline fail for stroke?
Mostly yes, in the form the field originally hoped for. Early European trials suggested benefit, but the large ICTUS trial in 2,298 acute ischemic stroke patients found no significant advantage over placebo at 90 days, and a 2020 Cochrane review of 10 RCTs concluded the evidence is low-quality with little to no clear effect. There is still a smaller signal for chronic post-stroke cognitive recovery in open-label trials, but acute stroke neuroprotection is not where the evidence landed.
Is citicoline safe long-term?
Available data look reassuring. The 12-week Nakazaki trial at 500mg/day and the 90-day COBRIT trial at 2000mg/day reported no serious safety signals, and the IDEALE study followed elderly patients for 9 months on 1000mg/day with good tolerability. Decades of clinical use in Europe and Japan support a benign safety profile. Watch for GI upset, mild insomnia if dosed late, and the rare bipolar-mania case reports.
Do I need to take citicoline with food?
No. Citicoline is well-absorbed orally with or without food. Most clinical trials did not specify food timing. If you find it gives you mild nausea, taking it with a meal solves that.
Sources
- McGlade E, Locatelli A, Hardy J, et al. Improved attentional performance following citicoline administration in healthy adult women. Food Nutr Sci. 2012;3:769-773.
- McGlade E, Agoston AM, DiMuzio J, et al. The effect of citicoline supplementation on motor speed and attention in adolescent males. J Atten Disord. 2019;23(2):121-134.
- Nakazaki E, Mah E, Sanoshy K, et al. Citicoline and memory function in healthy older adults: a randomized, double-blind, placebo-controlled clinical trial. J Nutr. 2021;151(8):2153-2160.
- Davalos A, Alvarez-Sabin J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380(9839):349-357.
- Zafonte RD, Bagiella E, Ansel BM, et al. Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. 2012;308(19):1993-2000.
- Marti-Carvajal AJ, Valli C, Marti-Amarista CE, et al. Citicoline for treating people with acute ischemic stroke. Cochrane Database Syst Rev. 2020;8:CD013066.
- Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging. 2013;8:131-137.
- Wurtman RJ, Regan M, Ulus I, Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. 2000;60(7):989-992.
- Bruce SE, Werner KB, Preston BF, Baker LM. Improvements in concentration, working memory and sustained attention following consumption of a natural citicoline-caffeine beverage. Int J Food Sci Nutr. 2014;65(8):1003-1007.
- Parisi V, Manni G, Colacino G, Bucci MG. Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology. 1999;106(6):1126-1134.
- Babb SM, Wald LL, Cohen BM, et al. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology. 2002;161(3):248-254.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products discussed on this page are not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any supplement regimen.